Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 4/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359225 | 1.00 | PARP10 (0.42) | PARP10GABRR1MAP4K4HTR1BCA12 | |
| SCHEMBL32677505 | 0.81 | CA1 (0.44) | CA12CA1CA2CA9CA14 | |
| SCHEMBL19359443 | 0.77 | HTR1D (0.44) | HTR1DKMT2AHTR1AHTR1E | |
| SCHEMBL19359558 | 0.77 | HTR1D (0.44) | HTR1DKMT2AHTR1AHTR1E | |
| SCHEMBL5151774 | 0.75 | SIGMAR1 (0.43) | ESR2KMT2A | |
| SCHEMBL19808113 | 0.75 | ESR2 (0.39) | ESR2 | |
| SCHEMBL17548224 | 0.75 | HTR2C (0.43) | CA12CA2CA9ESR2ALDH1A1 | |
| SCHEMBL14336758 | 0.74 | PLAU (0.41) | ESR2 | |
| SCHEMBL14755669 | 0.73 | PARP10 (0.44) | PARP10PARP15PARP2 | |
| SCHEMBL31489016 | 0.72 | CA1 (0.41) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | EPX, MPO, SERPINB1 | PARP10 978/4885GABRR1 3189/4885MAP4K4 1202/4885 |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | EPX, MPO, SERPINB1 | PARP10 978/4885GABRR1 3189/4885MAP4K4 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.